Number of the records: 1
Mitocans Revisited: Mitochondrial Targeting as Efficient Anti-Cancer Therapy
- 1.
SYSNO ASEP 0535784 Document Type J - Journal Article R&D Document Type Journal Article Subsidiary J Článek ve WOS Title Mitocans Revisited: Mitochondrial Targeting as Efficient Anti-Cancer Therapy Author(s) Dong, L. (AU)
Gopalan, V. (US)
Holland, O. (AU)
Neužil, Jiří (BTO-N) RIDNumber of authors 4 Article number 7941 Source Title International Journal of Molecular Sciences. - : MDPI
Roč. 21, č. 21 (2020)Number of pages 21 s. Language eng - English Country CH - Switzerland Keywords alpha-tocopheryl succinate ; overcoming drug-resistance ; cervical-cancer cells ; glutamine-metabolism ; mitochondrial targeting Subject RIV EB - Genetics ; Molecular Biology OECD category Biochemistry and molecular biology Method of publishing Open access Institutional support BTO-N - RVO:86652036 UT WOS 000589143400001 EID SCOPUS 85094117459 DOI 10.3390/ijms21217941 Annotation Mitochondria are essential cellular organelles, controlling multiple signalling pathways critical for cell survival and cell death. Increasing evidence suggests that mitochondrial metabolism and functions are indispensable in tumorigenesis and cancer progression, rendering mitochondria and mitochondrial functions as plausible targets for anti-cancer therapeutics. In this review, we summarised the major strategies of selective targeting of mitochondria and their functions to combat cancer, including targeting mitochondrial metabolism, the electron transport chain and tricarboxylic acid cycle, mitochondrial redox signalling pathways, and ROS homeostasis. We highlight that delivering anti-cancer drugs into mitochondria exhibits enormous potential for future cancer therapeutic strategies, with a great advantage of potentially overcoming drug resistance. Mitocans, exemplified by mitochondrially targeted vitamin E succinate and tamoxifen (MitoTam), selectively target cancer cell mitochondria and efficiently kill multiple types of cancer cells by disrupting mitochondrial function, with MitoTam currently undergoing a clinical trial. Workplace Institute of Biotechnology Contact Monika Kopřivová, Monika.Koprivova@ibt.cas.cz, Tel.: 325 873 700 Year of Publishing 2021 Electronic address https://www.mdpi.com/1422-0067/21/21/7941
Number of the records: 1